Facebook Twitter LinkedIn Google Plus RSS

Actavis announces settlement with AstraZeneca over generic drug

By ,

Specialty pharmaceutical company Actavis Inc., of Parsippany, announced today it has reached a settlement agreement with AstraZeneca resolving outstanding patent litigation.

The litigation concerned Actavis’ generic version of Crestor tablets.

Under the terms of the agreement, Actavis can launch its generic version of Crestor 67 days ahead of to July 8, 2016 — the expiration of pediatric exclusivity, at a fee of 39 percent of net sales to AstraZeneca. Launch of Actavis’ product is contingent upon the company receiving final approval from the Food and Drug Administration.

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!